BRCA1 and BRCA2 as prognostic markers in oral squamous cell carcinoma: a minireview
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985904%3A_____%2F25%3A00619151" target="_blank" >RIV/67985904:_____/25:00619151 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14310/25:00141128 RIV/61988987:17110/25:A2603CSI RIV/00843989:_____/25:E0111645
Výsledek na webu
<a href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1528822/full" target="_blank" >https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1528822/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fonc.2025.1528822" target="_blank" >10.3389/fonc.2025.1528822</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
BRCA1 and BRCA2 as prognostic markers in oral squamous cell carcinoma: a minireview
Popis výsledku v původním jazyce
Oral squamous cell carcinoma (OSCC), a subset of head and neck cancers, primarily originates in the epithelial tissues of the oral cavity. Despite advancements in treatment, the mortality rate for OSCC remains around 50%, underscoring the urgent need for improved prognostic markers. This review explores the role of the BRCA1 and BRCA2 genes-traditionally associated with breast and ovarian cancers-in the context of OSCC. We discuss the molecular pathways involving BRCA genes, their potential as diagnostics and prognostic biomarkers, and their implications for personalized treatment strategies, including addressing chemotherapy resistance. Furthermore, this review emphasizes the significance of genome stability in cancer progression and examines both current and emerging methodologies for detecting BRCA mutations in OSCC patients. Despite limited prevalence of BRCA mutations in OSCC compared to other cancers, their role in DNA repair and therapeutic response underscores their potential as clinical biomarkers. However, standardized, multicenter studies are still needed to validate their utility in OSCC management. A better understanding of the role of BRCA genes in OSCC could pave the way for more effective therapeutic approaches and improved patient outcomes.
Název v anglickém jazyce
BRCA1 and BRCA2 as prognostic markers in oral squamous cell carcinoma: a minireview
Popis výsledku anglicky
Oral squamous cell carcinoma (OSCC), a subset of head and neck cancers, primarily originates in the epithelial tissues of the oral cavity. Despite advancements in treatment, the mortality rate for OSCC remains around 50%, underscoring the urgent need for improved prognostic markers. This review explores the role of the BRCA1 and BRCA2 genes-traditionally associated with breast and ovarian cancers-in the context of OSCC. We discuss the molecular pathways involving BRCA genes, their potential as diagnostics and prognostic biomarkers, and their implications for personalized treatment strategies, including addressing chemotherapy resistance. Furthermore, this review emphasizes the significance of genome stability in cancer progression and examines both current and emerging methodologies for detecting BRCA mutations in OSCC patients. Despite limited prevalence of BRCA mutations in OSCC compared to other cancers, their role in DNA repair and therapeutic response underscores their potential as clinical biomarkers. However, standardized, multicenter studies are still needed to validate their utility in OSCC management. A better understanding of the role of BRCA genes in OSCC could pave the way for more effective therapeutic approaches and improved patient outcomes.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30208 - Dentistry, oral surgery and medicine
Návaznosti výsledku
Projekt
<a href="/cs/project/NV19-08-00383" target="_blank" >NV19-08-00383: Prognostické a prediktivní markery invaze spinocelulárních karcinomů dutiny ústní a orofaryngu</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2025
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Frontiers in Oncology
ISSN
2234-943X
e-ISSN
2234-943X
Svazek periodika
15
Číslo periodika v rámci svazku
MAR28
Stát vydavatele periodika
CH - Švýcarská konfederace
Počet stran výsledku
8
Strana od-do
1528822
Kód UT WoS článku
001463362700001
EID výsledku v databázi Scopus
2-s2.0-105002227069